Urogen Pharma (URGN) vs Vir Biotechnology, Inc. (VIR)
- Urogen Pharma URGN 34.56 −5.60%
- Vir Biotechnology, Inc. VIR 9.96 −4.87%
Urogen Pharma and Vir Biotechnology, Inc. are both Biotechnology companies. Urogen Pharma and Vir Biotechnology, Inc. are of similar size ($1.8B and $1.8B). Vir Biotechnology, Inc. grew revenue faster over the last twelve months: 1,495.9% against 100.3%. Urogen Pharma has the higher net margin (−51.7% vs −83.0%) and the higher return on invested capital (0.00% vs −39.1%). Across the 17 metrics below, Urogen Pharma leads on 9 and Vir Biotechnology, Inc. on 8.
Valuation
Profitability
| Metric | URGN | VIR | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.85% | 100.00% | 65.16% |
| Operating margin | (35.32%) | (92.40%) | 0.00% |
| Net margin | (51.73%) | (83.00%) | 0.00% |
| Free cash flow margin | (84.32%) | (67.17%) | 0.00% |
| Return on equity | 86.49% | (26.08%) | (56.36%) |
| Return on assets | (42.33%) | (20.91%) | (48.04%) |
| Return on invested capital | 0.00% | (39.10%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack